Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFNα in patients with metastatic melanoma

British Journal of Cancer

Volumn 88, Issue 2, 2003, Pages 175-180

  De Gast, G C ^a   Batchelor, D ^a   Kersten, M J ^a   Vyth Dreese, F A ^a   Sein, J ^a   Van De Kasteele, W F ^a   Nooijen, W J ^a   Nieweg, O E ^a   De Waal, M A ^a   Boogerd, W ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Immunotherapy; Malignant melanoma; Temozolomide

Indexed keywords

ALPHA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; INTERLEUKIN 2; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; FLU LIKE SYNDROME; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; LIVER DYSFUNCTION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MELANOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; DACARBAZINE; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; EYE NEOPLASMS; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; INTERFERON ALFA-2B; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; SKIN NEOPLASMS; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME;

EID: 0037468096     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600717     Document Type: Article

References (23)

1. Amer MH, Al-Sarraf M, Baker Lh, Vaitkevicius VK (1978) Malignant melanoma and central nervous system metastases. Cancer 42: 660-668
2. Bleehen NM, Newlands ES, Lee SM, Thatcher N, Selby P, Calvert AH, Rustin GJS, Brampton M, Stevens MFG (1995) Cancer research campaign phase 2 trial of temozolomide in metastatic melanoma. J Clin Oncol 13(4): 910-913
3. Caligiuri M, Zmuidzinas A, Manley TJ, Levine H, Smith KA, Ritz J (1990) Functional consequences of interleukin2 receptor expression on resting human lymphocytes. J Exp Med 171: 1509-1526
4. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, Begg CB, Agarwala SS, Schuchter LM, Ernstoff MS, Houghton AN, Kirkwood JM. (1999) Phase III Multicenter randomized trial of the dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17(9): 2745-2751
5. De Gast GC, Klümpen HJ, Vyth-Dreese FA, Kersten MJ, Verra NCV, Sein J, Batchelor D, Nooijen WJ, Schornagel JH (2000) Phase 1 trial of combined immunotherapy with subcutaneous GM-CSF, low dose IL2 and IFNα in progressive metastatic melanoma and renal cell carcinoma. Clin Cancer Res 6: 1267-1272
6. Dhodapkar M, Rubin J, Reid JM, Burch JC, Ames MM, Suman VJ (1997) Phase 1 trial of temozolomide (NSC 362856) in patients with advanced cancer. Clin Cancer Res 3(7): 1093-1100
7. Hammond LA, Eckardt JR, Baker SD, Eckhardt SG, Dugan M, Forral K, Reidenberg P, Statkevich P, Weiss GR, Rinaldi DA, Von Hoff DD, Rowinsky EK (1999) Phase 1 and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. J Clin Oncol 17(8): 2604-2613
8. Khayat D, Borel C, Tourani JM, Benhammouda A, Antoine E, Rixe O, Vuillemin E, Bazex PA, Thill L, Franks S, Auclerc G, Soubrane C, Banzet P, Weil M (1993) Sequential chemo-immunotherapy with cisplatin, interleukine-2 and interferon alfa-2a for metastatic melanoma. J Clin Oncol 12: 2173-2180
9. Lakhani S, Selby P, Bliss JM, Perren TJ, Gore ME, McElwain TJ (1990) Chemotherapy for malignant melanoma: Combinations and high doses produce more responses without survival benefit. Br J Cancer 61: 330-334
10. Legha SS (1997) Durable complete responses in metastatic melanoma treated with intefieukin-2 in combination with interferon alfa and chemotherapy. Sere Oncol; 24(2): S4-39-S4-43
11. Legha SS, Ring S, Eton O, Bedikian A, Buzaid AC, Plager C, Papadopoulas N (1998) Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 16: 1752-1759
12. Middleton MR, Grob JJ, Aaronson N Fiefibeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, Dreno B, Henz M, Schadendorf D, Kapp A, Weiss J, Fraass U, Statkevich P, Muller M, Thatcher N (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18(1): 158-166.
13. Nagler A, Lanier LL, Phillips JH (1990) Constitutive expression of high affinity interleukin2 receptors on human CD16 natural killer cells in vivo. J Exp Med 171: 1527-1533.
14. Newlands ES, Blackledge GRP, Slack JA, Rustin GJS, Smith DB, Stuart NSA, Quaterman CP, Hoffman R, Stevens MFG, Brampton FMH, Gibson AC (1992) Phase 1 trial temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 65: 287-291
15. O'Day SJ, Gammon G, Baasberg PD, Martin MA, Kristedja TS, Guo M, Stern S, Edwards S, Fournier P, Weisberg M, Cannon M, Fawzy NW, Johnson TD, Essner R, Foshaag LJ, Morton DJ (1999) Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocye colony-stimulating factor, and tamoxifen for patients with metastatic melanoma. J Clin Oncol 17(9): 2752-2761
16. O'Reilly SM, Newlands ES, Glaser MG, Brampton M, Rice-Edwards JM, Illingworth RD, Richards PG, Kennard C, Colquhoun IR, Lewis P, Stevens MFG (1993) Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumors. Eur J Cancer 29A(7): 940-942
17. Paul MJ, Summers Y, Calvert AH, Rustin G, Brampton MH, Thatcher N, Middleton MR (2002) Effect of Temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res 12: 175-178.
18. Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA (2001) Factors associated with response to high-dose Interleukin-2 in patients with metastatic melanoma. J Clin Oncol 19(8): 3477-3482
19. Richards JM, Gale D, Mehta N, Lestingi T (1999) Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma. J Clin Oncol 17(2): 651-657
20. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Seipp CA, Einhorn JH, White DE, Steinberg SM (1999) Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine and tamoxifen alone or in combination with interleukin-2 and interferon alfa. J Clin Oncol 17(3): 968-975.
21. Ryan L, Kramar A, Borden E (1993) Prognostic factors in metastatic melanoma. Cancer 10(5): 2995-3005
22. Stevens MFG, Hickman JA, Langdon SP et al. (1987) Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H0-one (CCRG 81045;M&B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 47: 5846-5852
23. Yung WKA, Prados MD, YayapTur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O'Neil AM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S, Levin VAJ (1999) Multicenter phase 2 trial of Temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol 17(9): 2762-2771